Physician profile
Anuj Bhatnagar
NPI 1316253180
$5,428.01
in general payments reported to CMS, 2019-2025
33 companies · $889 in 2025
The $889 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $417 · 2021: $616 · 2022: $634 · 2023: $1,019 · 2024: $1,016 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.07 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,027.17 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $879.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $593.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $411.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.26 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $241.56 | 2021-2025 | |
| Pfizer INC. | $232.02 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $226.66 | 2022-2023 | |
| Allergan, INC. | $141.66 | 2019-2020 | |
| Exact Sciences Corporation | $138.25 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $137.59 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $136.44 | 2019-2020 | |
| Cequr Corporation | $113.33 | 2023 | Cequr Simplicity |
| Amgen INC. | $106.87 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $104.61 | 2020-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $78.99 | 2021-2022 | |
| Glaxosmithkline, LLC. | $72.76 | 2022-2025 | Trelegy Ellipta |
| Boston Scientific Corporation | $52.09 | 2025 | Wavewriter Alpha Prime 16 |
| Xeris Pharmaceuticals, INC. | $42.93 | 2025 | Keveyis |
| Abbott Laboratories | $36.62 | 2023-2025 | Freestyle Libre 3 |
| Acadia Pharmaceuticals INC | $35.36 | 2019 | |
| Inspire Medical Systems, INC. | $27.10 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.05 | 2019-2020 | |
| Dexcom, INC. | $24.62 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $22.67 | 2025 | Bd Max System, Bd Max Instrument |
| Aerin Medical INC. | $20.66 | 2025 | |
| Ucb, INC. | $18.60 | 2019 | |
| Medtronic, INC. | $16.69 | 2023 | Closurefast |
| Eisai INC. | $15.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.01 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.39 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.